ACROBiosystems社 Supporting bispecific Checkpoint Inhibitor development
With the rise of bispecific drugs, there is a wave of research and development of dual-targeted based on PD-1 / PD-L1 and CTLA-4. Several researches have showed that anti-CTLA-4 inhibitors increase the expression of PD-L1 in some tumors and the combination of anti-CTLA-4 inhibition and PD-(L)1 inhibition favors effector T cell recruitment in preclinical tumor models. At present, there are many bispecific drugs in the clinical validation stage, such as MEDI5752, MGD019, KN046 and AK104. And its indications also cover a variety of solid tumors. Overall, these molecules potential new candidates to simultaneously block PD-1/PD-L1 and CTLA-4/B7 immune checkpoints pathway. hence mimicking the clinical effect of a dual immune checkpoint blockade. ACROBiosystems has specially launched a series of PD-(L)1 and CTLA-4 homodimer proteins, which are suitable for antibody screening and functional verification, to support the research and development of related targeted drugs. Assay Data
CTLA-4 homodimer structure and purity verified by SELC-MALS
Neutralizing antibody blocking assay
Quantitative Analysis of CTLA-4 x OX40 Bispecific Antibody in Human Serum by Intact Assay
|
Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。